For research use only. Not for therapeutic Use.
Molnupiravir (CAT: I008442) is a small-molecule antiviral drug that was originally developed for the treatment of influenza. It works by inducing errors in viral RNA replication, which leads to the accumulation of mutations and ultimately viral death. More recently, molnupiravir has gained attention as a potential treatment for COVID-19. It is being studied in clinical trials for its ability to inhibit replication of the SARS-CoV-2 virus and reduce viral load in patients with COVID-19.
| Catalog Number | I008442 |
| CAS Number | 2349386-89-4 |
| Synonyms | EIDD-2801; EIDD 1931-isopropyl ester; Lagevrio; MK-4482; Molnupiravir; β-D-N4 hydroxycytidine-5′-isopropyl ester |
| Molecular Formula | C13H19N3O7 |
| Purity | ≥95% |
| IUPAC Name | [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate |
| InChI | InChI=1S/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)16-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H,14,15,20)/t7-,9-,10-,11-/m1/s1 |
| InChIKey | HTNPEHXGEKVIHG-QCNRFFRDSA-N |
| SMILES | O[C@H]1[C@@H](O[C@H](COC(C(C)C)=O)[C@H]1O)N2C(=O)N/C(=NO)/C=C2 |
